On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s disease or for patients with mild cognitive impairment. This drug, lecanemab, moderately slows the rate of cognitive decline in a way that is noticeable to patients. The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC) led by…
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate a drug to treat agitation in Alzheimer’s patients. As reported by the hospital in a statement, the health center participates in the clinical trial 20AVP-786-307, which evaluates the tolerability of AVP786 to treat agitation in patients with Alzheimer’s. This is…
This study could improve the efficacy and safety of the products being evaluated to try to modify the progressive course of mild to moderate prodromal Alzheimer’s disease. In this research, which is identified with the name Brain shuttle, a solution to the difficulty of access of drugs inside the central nervous system is proposed. It…
Grifols has reported to the press the positive result of the AMBAR trial in patients with Alzheimer’s disease in a moderate phase. Our unit (located in the General University Hospital of Catalonia) participated in this phase II clinical trial. Patients were treated with several plasmapheresis and albumin replacement, with or without immunoglobulins administration, compared to…
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to reduce to 67% the selective tests. BARCELONA Given the difficulties of finding an effective treatment to cure Alzheimer’s disease, efforts to prevent the disease multiply. One of the entities that works in this line is the Pasqual Maragall Foundation, which…
We have been selected to evaluate an innovative therapy in this terrible disease. We will begin a Ib Phase clinical trial to evaluate the safety of an antiTau monoclonal antibody. If it is positive, we will participate in the development of the phase II trial to also check the efficacy and safety of different doses…
The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa, through continuous perfusion, to treat motor fluctuations in advanced Parkinson’s. For the first time, this use of an “ultra concentrated” levodopa that can allow its subcutaneous administration. The use of a continuous infusion pump can obtsin an adequate control of…